C

Calithera Biosciences Inc
F:2CB

Watchlist Manager
Calithera Biosciences Inc
F:2CB
Watchlist
Price: 3.86 EUR -2.53% Market Closed
Market Cap: 1m EUR
Have any thoughts about
Calithera Biosciences Inc?
Write Note

Intrinsic Value

2CB price has not been updated for more than 5 months. This may indicate that the stock has been delisted.
2CB doesn't have a meaningful market cap.

There is not enough data to reliably calculate the intrinsic value of 2CB.

The Intrinsic Value is calculated as the average of DCF and Relative values:

2CB Intrinsic Value
Not Available
C
Base Case Scenario
How do you feel about 2CB?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Calithera Biosciences Inc

Provide an overview of the primary business activities
of Calithera Biosciences Inc.

What unique competitive advantages
does Calithera Biosciences Inc hold over its rivals?

What risks and challenges
does Calithera Biosciences Inc face in the near future?

Summarize the latest earnings call
of Calithera Biosciences Inc.

Show all valuation multiples
for Calithera Biosciences Inc.

Provide P/S
for Calithera Biosciences Inc.

Provide P/E
for Calithera Biosciences Inc.

Provide P/OCF
for Calithera Biosciences Inc.

Provide P/FCFE
for Calithera Biosciences Inc.

Provide P/B
for Calithera Biosciences Inc.

Provide EV/S
for Calithera Biosciences Inc.

Provide EV/GP
for Calithera Biosciences Inc.

Provide EV/EBITDA
for Calithera Biosciences Inc.

Provide EV/EBIT
for Calithera Biosciences Inc.

Provide EV/OCF
for Calithera Biosciences Inc.

Provide EV/FCFF
for Calithera Biosciences Inc.

Provide EV/IC
for Calithera Biosciences Inc.

Show me price targets
for Calithera Biosciences Inc made by professional analysts.

What are the Revenue projections
for Calithera Biosciences Inc?

How accurate were the past Revenue estimates
for Calithera Biosciences Inc?

What are the Net Income projections
for Calithera Biosciences Inc?

How accurate were the past Net Income estimates
for Calithera Biosciences Inc?

What are the EPS projections
for Calithera Biosciences Inc?

How accurate were the past EPS estimates
for Calithera Biosciences Inc?

What are the EBIT projections
for Calithera Biosciences Inc?

How accurate were the past EBIT estimates
for Calithera Biosciences Inc?

Compare the revenue forecasts
for Calithera Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Calithera Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Calithera Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Calithera Biosciences Inc compared to its peers.

Compare the P/E ratios
of Calithera Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Calithera Biosciences Inc with its peers.

Analyze the financial leverage
of Calithera Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Calithera Biosciences Inc.

Provide ROE
for Calithera Biosciences Inc.

Provide ROA
for Calithera Biosciences Inc.

Provide ROIC
for Calithera Biosciences Inc.

Provide ROCE
for Calithera Biosciences Inc.

Provide Gross Margin
for Calithera Biosciences Inc.

Provide Operating Margin
for Calithera Biosciences Inc.

Provide Net Margin
for Calithera Biosciences Inc.

Provide FCF Margin
for Calithera Biosciences Inc.

Show all solvency ratios
for Calithera Biosciences Inc.

Provide D/E Ratio
for Calithera Biosciences Inc.

Provide D/A Ratio
for Calithera Biosciences Inc.

Provide Interest Coverage Ratio
for Calithera Biosciences Inc.

Provide Altman Z-Score Ratio
for Calithera Biosciences Inc.

Provide Quick Ratio
for Calithera Biosciences Inc.

Provide Current Ratio
for Calithera Biosciences Inc.

Provide Cash Ratio
for Calithera Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Calithera Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Calithera Biosciences Inc?

What is the current Free Cash Flow
of Calithera Biosciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Calithera Biosciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Calithera Biosciences Inc

Current Assets 26.6m
Cash & Short-Term Investments 25.5m
Other Current Assets 1.1m
Non-Current Assets 2.1m
PP&E 1.8m
Other Non-Current Assets 300k
Current Liabilities 7.4m
Accounts Payable 700k
Accrued Liabilities 6.7m
Non-Current Liabilities 900k
Other Non-Current Liabilities 900k
Efficiency

Earnings Waterfall
Calithera Biosciences Inc

Revenue
0 USD
Operating Expenses
-42.1m USD
Operating Income
-42.1m USD
Other Expenses
20.8m USD
Net Income
-21.3m USD

Free Cash Flow Analysis
Calithera Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

2CB Profitability Score
Profitability Due Diligence

Calithera Biosciences Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

18/100
Profitability
Score

Calithera Biosciences Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

2CB Solvency Score
Solvency Due Diligence

Calithera Biosciences Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
58/100
Solvency
Score

Calithera Biosciences Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

2CB Price Targets Summary
Calithera Biosciences Inc

There are no price targets for 2CB.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for 2CB?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for 2CB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Calithera Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1m EUR

Dividend Yield

0%

Description

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2014-10-02. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The firm is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The Company’s principal operations are based in South San Francisco, California. The company has a range of pipeline of small molecule drug candidates, which target enzymes controlling metabolically critical pathways in tumor cells and immune cells. The company has multiple internally discovered clinical stage compounds that are all enzyme inhibitors. The firm is engaged in developing telaglenastat in combination with standard therapies in a select set of solid tumors. Its lead development pathway for telaglenastat is for the treatment of KEAP1 or NRF2 mutated non-small cell lung cancer (NSCLC).

Contact

CALIFORNIA
South San Francisco
343 Oyster Point Blvd # 200
+16508701000.0
www.calithera.com

IPO

2014-10-02

Employees

63

Officers

Founder, CEO, Pres & Director
Dr. Susan M. Molineaux Ph.D.
CFO & Sec.
Ms. Stephanie Wong
Sr. VP of Drug Discovery
Dr. Eric B. Sjogren
Sr. VP of Devel.
Dr. Christopher J. Molineaux Ph.D.
Sr. VP of Research
Mr. Frank Parlati Ph.D.
Chief Medical Officer
Dr. Emil T. Kuriakose M.D.
Show More
Sr. VP of R&D Operations
Dr. Susan B. Demo Ph.D.
Sr. VP of Commercial & Portfolio Strategy
Dr. Allison Dillon Ph.D.
Show Less

See Also

Discover More